Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer

Eur J Clin Invest. 2022 Apr;52(4):e13721. doi: 10.1111/eci.13721. Epub 2021 Dec 7.

Abstract

Background: Repeated radiotherapy brings limited benefits and significant side effects for differentiated thyroid cancer patients (DTC) with radioiodine refractory (RAIR). However, the prognostic role of preoperative thyroglobulin (pre-Tg) in predicting RAIR is unclear.

Methods: In the present study, data were retrospectively reviewed from 5173 patients who underwent radiotherapy in the Jiangyuan Hospital from January 2006 to December 2020.

Results: A total of 1,102 patients with or without repeated radiotherapy were compared (repeated vs. single radiotherapy; n = 199 vs. n = 903). Pre-Tg was significantly elevated in patients with repeated radiotherapy. After the classification of RAIR (non-RAIR, n = 786 vs. RAIR, n = 90), elevated pre-Tg was also correlated with RAIR after univariate and multivariate analyses. According to the receiver operating characteristic curve analysis, elevated pre-Tg well predicted RAIR (AUC = 0.76, CI: 0.71-0.82, p < 0.0001). To control the selection bias, the propensity score matching was used. Pre-Tg level was found to be an independent predictor of RAIR (p < 0.001, HR = 7.25, CI: 2.55-20.62).

Conclusion: Our results indicate that markedly elevated pre-Tg level can be served as an independent predictor of RAIR-DTC, which can guide a more precise treatment strategy and/or an active surveillance during surgery and follow-ups.

Keywords: prognosis; radioiodine refractory; serum preoperative thyroglobulin; thyroid cancer.

MeSH terms

  • Female
  • Humans
  • Iodine Radioisotopes / therapeutic use*
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Preoperative Period
  • Retrospective Studies
  • Thyroglobulin / blood*
  • Thyroid Neoplasms / blood*
  • Thyroid Neoplasms / radiotherapy*
  • Treatment Failure

Substances

  • Iodine Radioisotopes
  • Thyroglobulin